1. Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors. Issue 12 (3rd November 2019) Authors: Sakata, Yoshihiko; Kawamura, Kodai; Ichikado, Kazuya; Shingu, Naoki; Yasuda, Yuko; Eguchi, Yoshitomo; Hisanaga, Jumpei; Nitawaki, Tatsuya; Iio, Miwa; Sekido, Yuko; Nakano, Aiko; Sakagami, Takuro Journal: Thoracic cancer Issue: Volume 10:Issue 12(2019) Page Start: 2259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer. (September 2016) Authors: Sakata, Yoshihiko; Kawamura, Kodai; Shingu, Naoki; Ichikado, Kazuya Journal: Lung cancer Issue: Volume 99(2016) Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT). (December 2021) Authors: Sakata, Yoshihiko; Sakata, Shinya; Oya, Yuko; Tamiya, Motohiro; Suzuki, Hidekazu; Shibaki, Ryota; Okada, Asuka; Kobe, Hiroshi; Matsumoto, Hirotaka; Yokoi, Takashi; Sato, Yuki; Uenami, Takeshi; Saito, Go; Tsukita, Yoko; Inaba, Megumi; Ikeda, Hideki; Arai, Daisuke; Maruyama, Hirotaka; Hara, Satoshi... Journal: European journal of cancer Issue: Volume 159(2021) Page Start: 144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON). (November 2021) Authors: Saito, Go; Oya, Yuko; Taniguchi, Yoshihiko; Kawachi, Hayato; Daichi, Fujimoto; Matsumoto, Hirotaka; Iwasawa, Shunichiro; Suzuki, Hidekazu; Niitsu, Takayuki; Miyauchi, Eisaku; Yokoi, Takashi; Yokoyama, Toshihide; Uenami, Takeshi; Sakata, Yoshihiko; Arai, Daisuke; Okada, Asuka; Nagata, Kenji; Terao... Journal: Lung cancer Issue: Volume 161(2021) Page Start: 86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study. (January 2023) Authors: Imaji, Mihoko; Fujimoto, Daichi; Sato, Yuki; Sakata, Yoshihiko; Oya, Yuko; Tamiya, Motohiro; Suzuki, Hidekazu; Ikeda, Hideki; Kijima, Takashi; Matsumoto, Hirotaka; Kanazu, Masaki; Hino, Aoi; Inaba, Megumi; Tsukita, Yoko; Arai, Daisuke; Maruyama, Hirotaka; Hara, Satoshi; Tsumura, Shinsuke; Kobe, H... Journal: European journal of cancer Issue: Volume 179(2023) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment. (April 2019) Authors: Sakata, Yoshihiko; Kawamura, Kodai; Ichikado, Kazuya; Shingu, Naoki; Yasuda, Yuko; Eguchi, Yoshitomo; Anan, Keisuke; Hisanaga, Junpei; Nitawaki, Tatsuya; Iio, Miwa; Sekido, Yuko; Nakano, Aiko; Sakagami, Takuro Journal: Lung cancer Issue: Volume 130(2019) Page Start: 159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The effects of switching EGFR‐TKI treatments for non‐small cell lung cancer because of adverse events. Issue 2 (2nd December 2018) Authors: Sakata, Yoshihiko; Kawamura, Kodai; Shingu, Naoki; Hiroshige, Shigeo; Yasuda, Yuko; Eguchi, Yoshitomo; Anan, Keisuke; Hisanaga, Junpei; Nitawaki, Tatsuya; Nakano, Aiko; Ichikado, Kazuya Journal: Asia-Pacific journal of clinical oncology Issue: Volume 16:Issue 2(2020) Page Start: e113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗